Cytopia zeroes in on brain
Monday, 17 November, 2008
Melbourne biotech Cytopia has commencing dosing patients in its Phase Ib/II trial of its vascular disrupting agent CYT997 in glioblastoma multiforme.
The trial will investigate the activity of CYT997 in combination with carboplatin and etoposide, common anti-cancer drugs.
CYT997 has been shown to ablate tumour blood vessels as well as inhibiting tubulin, thus affecting tumour cell replication. The compound is also being tested in multiple myeloma.
The trial will be held at Frankston Hospital in Victoria, with a second site in Sydney planned.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
